AC Immune has announced additional interim safety and positive immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056, its anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease (PD). Dr Andrea Pfeifer, CEO of AC Immune, commented: “We continue to be encouraged by the data… Read More
Dr Jason Williams, Founder and Director of Interventional Oncology and Immunotherapy at The Williams Cancer Institute, discusses leveraging immunotherapy and cryoablation for a new era in cancer treatment. The paradigm of cancer treatment is shifting. For decades, chemotherapy and radiation have been the pillars of oncology, but their limitations are becoming… Read More
An experimental cancer treatment developed by researchers at the Melanoma Institute Australia paves the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne. It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of… Read More
Swarm Oncology and Cellex Cell Professionals have announced a new partnership with a particular focus on clinical and commercial supply of T cell therapies. Despite advancements in oncology, more than 82% of patients with advanced metastatic cancer ultimately succumb to their disease. Current immunotherapies provide only limited survival benefits due… Read More
Giusy Di Conza, Head of Research at iOnctura, explores the challenges of current immunotherapy approaches for cancer and where opportunity lies. Immunotherapy has transformed modern oncology. Immune checkpoint inhibitors like pembrolizumab and nivolumab revolutionised melanoma treatment by enhancing immune responses; ensuring it could become a manageable disease - with improved… Read More
University of Queensland researchers have discovered that immunotherapy, when used to treat people with advanced cancers, also helps reduce sunspots and skin cancers by at least 65%. Over 12 months, researchers monitored 23 patients receiving immunotherapy for unrelated cancers and found the treatment also targeted cancerous and… Read More
The amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy, new research has revealed. If integrated into the clinic, the researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, say testing for… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early… Read More
News round-up for 13-17 January by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of positive announcements related to the early clinical and preclinical development of immunotherapies, including an islet cell therapy for diabetes, an antibody-drug conjugate and a CAR-T therapy for… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “… Read More
This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More
This is the latest episode of the free DDW narrated podcast, titled ‘Exciting start-ups and developments in drug discovery’, which covers two articles written for DDW Volume 24 – Issue 1, Winter 2022/2023. They are called: ‘What Lithuania offers life sciences start-ups’ and ‘… Read More
Immunotherapy developer Centauri Therapeutics has been awarded a £1 ($1.2) million grant by Pathways to Antimicrobial Clinical Efficacy (PACE), an initiative focused on early-stage antimicrobial drug and diagnostic discovery. The funding will support the continued development of Centauri’s Alphamer technology, in this case targeting gram-negative bacteria including multi-drug resistant (MDR)… Read More
Megan Thomas explores the innovation and opportunity for cancer vaccines with Dr Alexander Zehnder, CEO of CureVac, and Dr Chris Haqq, Chief Medical Officer of Elicio Therapeutics. It could be argued that Covid-19 gave us a boost to start making headway in cancer vaccines. Between the acceleration of mRNA vaccine… Read More
Dr Jill O’Donnell Tormey, CEO and Director of Scientific Affairs at the Cancer Research Institute, US, discusses the future of cancer research with DDW's Megan Thomas. Innovation & opportunity Reflecting on innovation and opportunity in global cancer research, Dr Jill O’Donnell-Tormey recognises modalities like cell therapies, bispecifics, antibody drug conjugates… Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the Society for Immunotherapy of Cancer (SITC) 2024 taking place in Houston… Read More
